Revolutionized liquid biopsy cancer testing
"It's a rapid answer, it’s less invasive, it’s something that can be used in addition to the molecular information from the tumor, it has all those advantages.”
William Morice II, M.D., Ph.D., CEO and President of Mayo Clinic Laboratories
Potentially transformative testing: Patient cases
From diagnosis and therapy selection to monitoring treatment response and detecting emerging mutations that increase disease burden over time, LiquidHALLMARK® provides results that could change lives.
From critically ill to cancer clearance
Background
- A 50-year-old woman with lung cancer was critically ill and mechanically ventilated in the intensive care unit.
- The patient had palpable cervical lymph nodes; however, a lymph node biopsy did not recover adequate tissue for molecular testing.
Testing and treatment
- An FDA-approved ctDNA liquid biopsy did not identify treatment targets.
- LiquidHALLMARK® testing (ctDNA + ctRNA), which delivered results in seven days, identified an actionable ALK fusion.
- ALK-targeted therapy was initiated.
Outcome
- One year after treatment initiation, the patient had no disease progression.
- The patient was weaned off ventilation and eventually discharged.
- Six months after ALK-targeted therapy, PET imaging showed significantly diminished tumor activity.
Discovering and overcoming treatment resistance with serial monitoring
Background
- A 30-year-old woman has metastatic lung cancer.
Testing and treatment
- Baseline LiquidHALLMARK® testing detected an EGFR exon 19 complex in-frame indel.
- Patient begins osimertinib treatment.
- After two years of treatment response, treatment monitoring using LiquidHALLMARK® detects an EML4-ALK fusion resistance mutation.
- The patient begins crizotinib treatment.
Outcome
- LiquidHALLMARK® testing (ctDNA + ctRNA) was performed over a two-year span, helping to enable a good response to therapy, with no further detection of EGFR indel in ctDNA.
All case studies are for educational, scientific presentation purposes only, and individual case outcomes and results may vary.
Industry-leading innovation
In addition to detecting ctRNA targets, LiquidHALLMARK® liquid biopsy testing uses an error-correction technology called AmpliMark™ that uses unique molecular barcodes to improve detection of multiple mutation types, such as single nucleotide variants, insertions and deletions (indels), copy number variations (CNVs), fusions, and microsatellite instability (MSI).
When compared head-to-head with similar commercially available liquid biopsy testing, LiquidHALLMARK® offers advantages over other testing on the market. As part of the LIQUIK trial, LiquidHALLMARK® ctDNA + ctRNA liquid biopsy:
- Detected 15.6% (52 versus 45) more tissue-confirmed guideline-recommended biomarkers than FDA-approved ctDNA-only liquid biopsy.
- Improved fusion detection due to the inclusion of ctRNA analysis by 28.6%.
Groundbreaking collaborations
LiquidHALLMARK® liquid biopsy was developed by and offered in collaboration with Lucence. Through partnerships with patient-centric pioneers like Lucence, Mayo Clinic Laboratories seeks to strengthen clinical practice, advance medical knowledge, and enhance healthcare for all.
Increase your awareness of next-level liquid biopsy testing.
Explore how LiquidHALLMARK® liquid biopsy testing can provide you with a deeper understanding of your patient’s cancer and how best to treat it. Schedule a time to discuss with one of our clinical specialists.
Highlights
LiquidHALLMARK combines DNA and RNA for more accurate cancer profiling, helping patients access lifesaving therapies.
Join us for a webinar exploring how LiquidHALLMARK®, a cutting-edge liquid biopsy test, is transforming cancer care.
In the first quarter of 2025, Mayo Clinic Laboratories expanded its test catalog with several innovative new tests.
In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, invited Min-Han Tan, M.B.B.S., FRCP, Ph.D., founding CEO and medical director of Lucence, to discuss liquid biopsy cancer testing. Mayo Clinic Laboratories and Lucence recently announced a collaboration to expand access to this cutting-edge cancer test that is designed to detect clinically relevant biomarkers in ctDNA and ctRNA.
Mayo Clinic Laboratories and Lucence are expanding access to advanced cancer testing worldwide with LiquidHALLMARK®, a next-generation liquid biopsy that provides actionable genomic insights. This collaboration empowers physicians to deliver personalized care and improve patient outcomes.
Resources
References
- Samol J, et al. Prospective multicenter study evaluating a combined circulating tumor DNA and circulating tumor RNA liquid biopsy in metastatic non–small cell lung cancer (LIQUIK). JCO Precis Oncol 9, e2500181(2025). doi:10.1200/PO-25-00181
- Samol J, et al. PP01.74 LiquidHALLMARK® detects more tissue-confirmed guideline-recommended biomarkers than Guardant360 for lung cancer: a prospective multicenter study. JTO. 2024; 19(7): E34-E35.
Credit: LiquidHALLMARK® is a trademark or registered trademark of Lucence Health Inc. and/or its affiliates in the U.S. and other countries and is used under license.